Allarity Therapeutics announced publication of two AACR 2026 posters highlighting stenoparib's potential in colorectal cancer via WNT pathway modulation and DRP® association with enhanced overall survival in ovarian cancer patients.
Key takeaways
Published two posters at AACR 2026 Annual Meeting (April 17–22, San Diego) now available on company website.
Poster 1: Stenoparib-DRP® scores linked to enhanced overall survival in phase 2 ovarian cancer trial (NCT03878849).
Poster 2: Stenoparib inhibits WNT/β-catenin pathway and colorectal cancer cell growth at clinically relevant concentrations.
Ongoing phase 2 trials: stenoparib in ovarian cancer (platinum-resistant) and in combination with temozolomide for SCLC.
CEO Thomas Jensen emphasized stenoparib's potential in colorectal cancer and DRP® for patient selection.